Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF MEDICAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 69,922 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,497 · Balance 68,120 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,624 · Balance 69,744 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 71,494 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 73,951 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,029 · Balance 69,922 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,700 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 6,700 · Balance 6,700 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,500 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 3,500 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,624 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,624 · Balance 1,624 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,497 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 26,750 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 26,750 · Balance 26,750 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2022 Filed Apr 11, 2022 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003995 · form4-04112022_010455.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,990 Underlying: Class A Common Share · 9,990 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 59,930 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-22-003995 · form4-04112022_010455.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,930 Underlying: Class A Common Share · 59,930 shares Expires 2032-04-06 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 5,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003283 · form4-03232022_040310.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 5,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,686 | $10.98 | $18,512.28 |
DisclosureSEC source: 0001415889-22-003283 · form4-03232022_040310.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,117 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 5,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-003283 · form4-03232022_040310.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002327 · edgar.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,175 Underlying: Class A Common Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 598 | $10.13 | $6,057.74 |
DisclosureSEC source: 0001179110-22-002327 · edgar.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,127 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002327 · edgar.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008646 · edgar.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Class A Common Shares · 6,900 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 41,400 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001179110-21-008646 · edgar.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,400 Underlying: Class A Common Shares · 41,400 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003732 · edgar.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,671 Underlying: Class A Common Shares · 3,671 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 5,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003732 · edgar.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,676 Underlying: Class A Common Shares · 5,676 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003617 · edgar.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Class A Common Shares · 6,900 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 41,400 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001179110-21-003617 · edgar.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,400 Underlying: Class A Common Shares · 41,400 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 21:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 50,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001179110-20-009721 · edgar.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Shares · 50,000 shares Expires 2030-09-09 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 50,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001179110-20-003833 · edgar.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Shares · 50,000 shares Expires 2030-03-12 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 12,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001179110-20-002714 · edgar.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,574 Underlying: Class A Common Shares · 12,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant of 227,574 Class A Common Shares on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is August 15, 2016. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 12,000 | $1.86 | $22,320.00 |
DisclosureSEC source: 0001179110-20-002714 · edgar.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 9,803 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · derivative · entry 7 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,542 Underlying: Class A Common Shares · 9,803 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F5 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 1,116 | $19.32 | $21,561.12 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.31 to $19.37. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 8,687 | $18.91 | $164,271.17 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,116 F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.30 to $19.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 9,803 | $3.80 | $37,251.40 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 22,477 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,345 Underlying: Class A Common Shares · 22,477 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F5 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 22,477 | $18.27 | $410,654.79 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 22,477 | $3.80 | $85,412.60 |
DisclosureSEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 1,039 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001179110-20-001763 · edgar.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,822 Underlying: Class A Common Shares · 1,039 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F2 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 1,039 | $18.33 | $19,044.87 |
DisclosureSEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F4 · shares: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.47. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 1,039 | $3.80 | $3,948.20 |
DisclosureSEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,277 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001179110-20-001763 · edgar.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,861 Underlying: Class A Common Shares · 10,277 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F2 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 10,277 | $18.29 | $187,966.33 |
DisclosureSEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. F3 · shares: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 10,277 | $3.80 | $39,052.60 |
DisclosureSEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001179110-19-012550 · edgar.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,574 Underlying: Class A Common Shares · 8,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant of 227,574 Class A Common Shares on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is August 15, 2016. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 8,000 | $1.86 | $14,880.00 |
DisclosureSEC source: 0001179110-19-012550 · edgar.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001179110-19-010889 · edgar.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,574 Underlying: Class A Common Shares · 10,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant of 227,574 Class A Common Shares on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is August 15, 2016. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 10,000 | $1.86 | $18,600.00 |
DisclosureSEC source: 0001179110-19-010889 · edgar.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 46,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001179110-19-010486 · edgar.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Class A Common Shares · 46,000 shares Expires 2029-09-16 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:29 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 51,000 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001104659-19-013175 · a4.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Common Shares · 51,000 shares Expires 2029-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 12:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 45,000 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001104659-18-058110 · a4.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2028-09-19 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.